$NuCana (NCNA.US)$ two catalyst, FIRST, it would be from Aug...
$NuCana (NCNA.US)$ two catalyst,
FIRST, it would be from Aug-Dec 2024
We are pleased to report that all three studies are progressing as planned, and we look forward to sharing data updates in the second half of 2024.”
SECOND
Mr. Griffith continued: “In addition, NUC-7738, a ProTide transformation of a novel nucleoside analog, 3’-deoxyadenosine, is being assessed in the Phase 2 part of the ongoing Phase 1/2 NuTide:701 study in PD-1 inhibitor-resistant melanoma patients. Following a positive data update at the American Association for Cancer Research (AACR) Annual Meeting earlier this year, we plan to announce additional data at the upcoming European Society for Medical Oncology (ESMO) Congress 2024, being held September 13-17 in Barcelona, Spain.”
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
